Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
US11834453B2 · kind B2 · utility
0Cited by
0References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 29, 2021 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Jun 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.